Sernova – Patentierte Zelltaschen mit Schutzschild gegen die Immunabwehr ! (Seite 841)
eröffnet am 24.06.15 16:59:24 von
neuester Beitrag 28.05.24 21:09:24 von
neuester Beitrag 28.05.24 21:09:24 von
Beiträge: 8.627
ID: 1.214.676
ID: 1.214.676
Aufrufe heute: 515
Gesamt: 1.084.924
Gesamt: 1.084.924
Aktive User: 2
ISIN: CA81732W1041 · WKN: A0LBCR
0,2150
EUR
+5,91 %
+0,0120 EUR
Letzter Kurs 22:33:12 L&S Exchange
Neuigkeiten
| TitelBeiträge |
|---|
19:12 Uhr · Shareribs Anzeige |
13:02 Uhr · IRW Press |
24.05.24 · Shareribs Anzeige |
22.05.24 · Shareribs Anzeige |
Werte aus der Branche Gesundheitswesen
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,5172 | +142,02 | |
| 8,00 | +119,60 | |
| 3,25 | +44,44 | |
| 2,0600 | +32,05 | |
| 2,0400 | +29,98 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,2300 | -14,23 | |
| 1,7500 | -14,63 | |
| 14,170 | -14,89 | |
| 0,5200 | -38,82 | |
| 0,9000 | -53,85 |
Beitrag zu dieser Diskussion schreiben
Feedback
der Stuttgarter Makler lässt die Deutschen besser zum Zuge kommen. Frankfurt Briefseite zu hoch.
Antwort auf Beitrag Nr.: 57.742.663 von marius777 am 11.05.18 18:40:32Tageshoch 0,42 CAD
siehe Beitrag 222 - eine Menge News in der Pipeline.
Ich kann ein neues 52 Hoch schon förmlich riechen
siehe Beitrag 222 - eine Menge News in der Pipeline.
Ich kann ein neues 52 Hoch schon förmlich riechen
okay... wie sagen die jungs in der krypto-szene!? to the moon!!!!!!!das ding geht steil. frage, ob dasnur fomo ist, oder ob der kursanstieg auch eine nachhaltigkeit nach sich zieht. dachte mir heute morgen im büro, nach dem ich den artikel gelesen hatte, warte mal ab, wenn nordamerika aufwacht.... scheint zu stimmen, dass die überm atlantik auch in kauflaune sind :-)
0,38 in Kanada
Trading Spotlight
Research and Development Outlook for the 2018 Calendar Year
Our research and development program for 2018 includes the following:
- Initiate a clinical trial of our Cell Pouch™ in collaboration with JDRF under our recently
cleared US IND for patients with hypoglycemia unawareness using human donor islets and a
standard of care antirejection drug regimen to further study the safety and efficacy of the device
and islets;
- Clinical evaluation of the Cell Pouch™ for insulin-dependent diabetes who have received an
islet transplant;
- In coordination with the EU Horizon 2020 HemAcure Consortium. conduct cell production
and preclinical studies for treatment of hemophilia A consisting of factor VIII releasing
therapeutic cells transplanted within Sernova’s Cell Pouch™;
- Conduct preclinical studies for treatment of hypo-thyroid disease consisting of thyroid
hormone releasing tissue transplanted within Sernova’s Cell Pouch™;
- Production of human stem-cell-derived cells for diabetes and in vivo proof of principle
assessment of these differentiated human stem cells for their safety and efficacy within
Sernova’s Cell Pouch™ for the treatment of insulin-dependent diabetes;
- Assessment of novel microencapsulation technologies within the Cell Pouch™ cells, to further
develop and advance Sernova’s therapeutic vision for diabetes of a product consisting of
locally immune protected therapeutic cells within the Cell Pouch™; and
- Continue to collaborate with pharmaceutical companies to assess safety and efficacy of our
combined technologies in preclinical studies for potential negotiation of a licensing
arrangement and commercial development partnership for our hemophilia and diabetes
programs.
Quelle: letzter Quartalsbericht
Our research and development program for 2018 includes the following:
- Initiate a clinical trial of our Cell Pouch™ in collaboration with JDRF under our recently
cleared US IND for patients with hypoglycemia unawareness using human donor islets and a
standard of care antirejection drug regimen to further study the safety and efficacy of the device
and islets;
- Clinical evaluation of the Cell Pouch™ for insulin-dependent diabetes who have received an
islet transplant;
- In coordination with the EU Horizon 2020 HemAcure Consortium. conduct cell production
and preclinical studies for treatment of hemophilia A consisting of factor VIII releasing
therapeutic cells transplanted within Sernova’s Cell Pouch™;
- Conduct preclinical studies for treatment of hypo-thyroid disease consisting of thyroid
hormone releasing tissue transplanted within Sernova’s Cell Pouch™;
- Production of human stem-cell-derived cells for diabetes and in vivo proof of principle
assessment of these differentiated human stem cells for their safety and efficacy within
Sernova’s Cell Pouch™ for the treatment of insulin-dependent diabetes;
- Assessment of novel microencapsulation technologies within the Cell Pouch™ cells, to further
develop and advance Sernova’s therapeutic vision for diabetes of a product consisting of
locally immune protected therapeutic cells within the Cell Pouch™; and
- Continue to collaborate with pharmaceutical companies to assess safety and efficacy of our
combined technologies in preclinical studies for potential negotiation of a licensing
arrangement and commercial development partnership for our hemophilia and diabetes
programs.
Quelle: letzter Quartalsbericht
Antwort auf Beitrag Nr.: 57.724.705 von sneakee am 09.05.18 10:14:14vielleicht hier noch was zu Deiner Frage in Sachen Finanzierung:
"Our model assumes that cumulative economics from future Cell Pouch partners could contribute $70-75M in non-dilutive capital during F2019-F2028."
Quelle: obiger Echelon Wealth Report
"Our model assumes that cumulative economics from future Cell Pouch partners could contribute $70-75M in non-dilutive capital during F2019-F2028."
Quelle: obiger Echelon Wealth Report
Peergroup hat im Schnitt 653 Millionen Börsenwert, Sernova weniger als 60 Millionen
ich hoffe, dass das halbwegs lesbar ist - komplette Studie habe ich hier, wer ein pdf will
Durchsuchen
